Key Takeaways Prep smarter with real-world coding challenges, system design scenarios, and behavioral questions tailored for top-tier tech roles and startups.Bo ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical ...

In an effort to save costs and make its financial resources last longer, Recursion Pharmaceuticals (NASDAQ: RXRX) is slimming ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of ...

Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to ...

Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.

After layoffs at Recursion, the company’s CEO writes about taking inspiration from an unexpected source: “The Art of Racing ...

Recursion Pharmaceuticals said on Tuesday it will lay off around 20% of its workforce and focus on developing drugs for rare diseases and cancers to reduce cash burn during a prolonged biotech ...

Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) traded higher in the premarket on Tuesday after the AI-driven biotech ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...